A child can drown in seconds. Doctors want more families to be prepared
medicalxpress - Doctors and others are sounding an alarm: More U.S. children have been drowning in recent years.
AI Summary: Toddlers can slip beneath the surface faster than anyone expects; clinicians are urging families to stop assuming “it won’t happen to us.” They recommend constant supervision near water, basic CPR training, secure barriers, life jackets for non-swimmers, and wider public education to prevent rapid, often silent drowning incidents. Practical steps save lives—no heroics required.
The US is hooked on unregulated peptides. But are they effective, or even safe?
livescience - The world of peptides has exploded in wellness circles, but the benefits of injecting these gray-market molecules rest on little clinical evidence.
AI Summary: Unregulated peptide products have proliferated in the US, raising safety and efficacy concerns as federal regulators convene a contentious panel that includes proponents of these off‑label compounds. The debate highlights a market gap where hype often outpaces evidence — and where regulators must decide whether to tidy up the wild west or watch it fester.
CheckMate 214 Updates: Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced RCC
oncodaily - First-line treatment for advanced renal cell carcinoma has changed substantially with the use of immune checkpoint inhibitor-based regimens. Long-term follow-up is important to show whether these early survival and response […]
AI Summary: Long‑term CheckMate‑214 data comparing nivolumab plus ipilimumab against sunitinib in advanced renal cell carcinoma show sustained survival benefits for the immunotherapy combination at nine years. The follow‑up reinforces durable responses in a defined subgroup, helping clinicians refine long‑term treatment sequencing and expectations for metastatic RCC.
Evernorth unveils new AI-powered specialty pharmacy program, Pharmacy Forward
fiercehealthcare - Evernorth has unveiled a new specialty pharmacy program that leans on AI to support a better experience for patients with complex conditions.
AI Summary: Evernorth announced a $100 million investment to roll out an AI‑driven specialty pharmacy program designed to streamline specialty drug management, improve medication access, and optimize operations. The program blends automation and data analytics to cut friction in high‑cost therapies — promising efficiency gains if the tech behaves, which is always the question.
Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine
Frank Vinluan / medcitynews - FDA approval of Orca Bio’s Tregzi makes it the first cell therapy based on regulatory T cells, or Tregs. Clinical trial results showed reduced risk of graft-versus-host disease, a common complication of the allogeneic stem cell transplants that are a stan…
AI Summary: Orca Bio’s off‑the‑shelf allogeneic cell therapy received FDA approval, marking a milestone for engineered living medicines. Regulators cleared the product after pivotal efficacy and manufacturing data, offering broader access to cellular therapy but spotlighting cost, supply logistics and the need for robust post‑market safety surveillance.
'Polypill' for heart failure cuts hospitalizations and ER visits by 60% in trial
medicalxpress - A "polypill" combining three medications recommended to treat heart failure into a single daily dose proved far more effective for patients than taking the drugs separately, a randomized clinical trial led by UT Southwestern Medical Center researchers sho…
AI Summary: The POLY‑HF randomized trial found that a fixed‑dose 'polypill' for heart failure with reduced ejection fraction cut hospitalizations and emergency visits by roughly 60%, improving adherence and standardizing therapy. Results suggest a pragmatic, low‑complexity intervention could deliver substantial health‑system benefits if adopted broadly and monitored for implementation challenges.
American Hospital Association names Steve Walsh as next CEO
fiercehealthcare - Walsh is currently the head of the Massachusetts Hospital Association, and will be taking the national stage at a moment of substantial policy and political challenges for the hospital industry.
AI Summary: Steve Walsh was named the next CEO of the American Hospital Association, replacing outgoing leadership and signaling continuity with a public-sector advocacy background. The appointment centers on navigating hospital policy, membership priorities and advocacy at a time of industry consolidation and regulatory pressure — yes, more meetings and memos ahead.
ACA marketplace enrollment down by 3M as of February, new federal data show
fiercehealthcare - New federal data show that 19.2 million individuals were enrolled in Affordable Care Act marketplace plans as of February, down by nearly 3 million from 2025.
AI Summary: New federal data show ACA marketplace enrollment fell by roughly three million people as of February, signaling continuing declines in the individual market. Officials cite affordability, policy and outreach gaps as contributing factors, leaving consumers with narrower plan choices and potential cost pressure. The drop revives debate over measures to stabilize enrollment and access.
- ACA enrollment drops by about 3 million (5)
- Insurers seek median 14% ACA premium increases in 2027 (6)
- All Other Stories
ACA enrollment drops by about 3 million
Insurers seek median 14% ACA premium increases in 2027
All Other Stories
French deaths soar as extreme heat breaks European records
abcnews - The head of the WHO warns that Europe must do more to protect people.
AI Summary: An intense European heatwave drove record temperatures, a rise in heat‑related deaths and urgent public‑health messaging. Hospitals and public services warned of high-risk exposures, provided heat‑illness guidance and advised behavioral changes — from skipping strenuous exercise to treating heat exhaustion — as cities scrambled to protect vulnerable residents and frantically retrofit cooling advice into everyday life.
Cancer drug shortage renews calls for federal action
medicalxpress - Cancer doctors across the United States are running short of essential generic chemotherapy drugs, and some fear the squeeze could force widespread rationing, The New York Times reported.
AI Summary: Hospitals and oncology clinics are facing critical shortages of key chemotherapy agents, forcing clinicians to consider rationing or alternative regimens. The supply squeeze has reignited demands for federal intervention, supply‑chain fixes, and clearer contingency plans to protect patients who can’t exactly wait for bureaucratic miracles.
A Bridge to Nowhere? Medicare’s GLP-1 Coverage Expansion Requires A More Holistic Approach To Weight Management
Sandeep Palakodeti / medcitynews - For seniors, the change in policy will dramatically expand access to a revolutionary medication. But there are also significant risks.The post A Bridge to Nowhere? Medicare’s GLP-1 Coverage Expansion Requires A More Holistic Approach To Weight Management …
AI Summary: Medicare’s planned GLP‑1 coverage “bridge” has kicked off a scramble: policy analysts warn a narrow drug‑centric approach won’t fix weight management, while major retailers are rolling out programs and partnerships to plug access gaps. Expect patchwork solutions, eager pharmacies, and a chorus asking for a more holistic long‑term plan.
- Clinical risks and long-term effectiveness debate (5)
- Medicare Bridge rollout, eligibility and cost questions (5)
- Online prescribing, oversight and soaring GLP‑1 use (4)
- Retailers, pharmacies and manufacturers rush to plug access gaps (4)
- All Other Stories
Clinical risks and long-term effectiveness debate
Medicare Bridge rollout, eligibility and cost questions
Online prescribing, oversight and soaring GLP‑1 use
Retailers, pharmacies and manufacturers rush to plug access gaps
All Other Stories
RWJBarnabas Health, Rutgers open $225M cancer center
Elizabeth Gregerson / beckershospitalreview - On June 22, West Orange, N.J.-based RWJBarnabas Health and New Brunswick, N.J.-based Rutgers Cancer Institute opened the Melchiorre Cancer Center at Cooperman Barnabas Medical Center in Livingston, N.J. The cancer center cost $225 million, according to a …
AI Summary: Results presented at ASCO for daraxonrasib delivered practice‑changing evidence in pancreatic cancer, prompting clinicians to offer the drug off‑trial within weeks. The data generated excitement across conferences and clinical teams, fueling early adoption discussions and raising hopes for a tangible advance against a historically stubborn disease.
- ASCO shockwave: Daraxonrasib survival curve draws standing ovation (3)
- Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing (4)
- Conference context: RAS momentum and expert reflections (5)
- Rapid off‑trial rollout and early patient access (4)
- All Other Stories
ASCO shockwave: Daraxonrasib survival curve draws standing ovation
Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing
Conference context: RAS momentum and expert reflections
Rapid off‑trial rollout and early patient access
All Other Stories
AI system detects sudden cardiac death risk, identifying thousands more patients annually
medicalxpress - Each year in the U.S., more than 300,000 people die from sudden cardiac arrest, a condition in which the heart's electrical system malfunctions without warning. The medical emergency can kill both high-risk older adults and young athletes with no history …
AI Summary: New AI tools claim to identify far more patients at risk of sudden cardiac death than traditional metrics, detecting subtle patterns invisible to clinicians. Early studies suggest strong sensitivity gains, but experts caution that screening scale‑up, false positives and prospective validation will determine whether the tech saves lives or simply creates more testing.
FDA Approves Gilead’s Trodelvy, Alone and With Merck’s Keytruda, in First-Line Metastatic TNBC
oncodaily - Decision delivers the first ADC-based regimens for previously untreated triple-negative breast cancer across PD-L1 status, a PD-L1-positive Keytruda combination plus a monotherapy option for immunotherapy-ineligible patients. The U.S. Food and […]
AI Summary: The FDA approved sacituzumab govitecan (Trodelvy) as both monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of metastatic triple‑negative breast cancer, expanding options for a hard-to-treat population. Regulators cited clinical benefit in appropriate patients, reshaping treatment sequencing and payer discussions.
A Ban Won’t Stop Abortion Pill Access, Telehealth Providers Say
Kate Wells / kffhealthnews - As a federal court mulls a case that could result in significant restrictions on a pill used in most abortions, providers say they have alternatives to preserve access even in states with bans in place.
AI Summary: Providers and telehealth advocates warn that banning access won’t stop patients from obtaining abortion pills online. Telemedicine and pharmacy workarounds continue to provide routes for care, underscoring limits of state bans and foreshadowing prolonged legal and practical battles over remote prescribing, cross‑border services, and patient privacy.
As PBM industry shifts, LucyRx and Abarca Health merge to build scale
fiercehealthcare - Amid significant shifts in the pharmacy benefit management industry, LucyRx and Abarca Health have revealed plans to merge to build the scale necessary to compete in this changing landscape.
AI Summary: Two independent pharmacy benefit managers, LucyRx and Abarca Health, announced a combination to build scale amid industry consolidation. The deal aims to bolster negotiating leverage, broaden client reach and offer an alternative to dominant PBMs—because apparently one disruptor wasn’t enough to disrupt the disruptors.
FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC
esmo -
AI Summary: Regulators have approved datopotamab deruxtecan for patients with unresectable or metastatic triple‑negative breast cancer, offering a new targeted option where few exist. The decision follows trial evidence of meaningful anti‑tumor activity and expands the treatment toolkit for aggressive TNBC subtypes, with clinicians weighing sequencing and toxicity management.
Ashok Sebastian Komaranchath: Delighted to Speak at the 5th International Oncology Forum on 20–21 June 2026
oncodaily - Ashok Sebastian Komaranchath, Consultant Medical Oncology and Clinical Lead for Oncology Services at Burjeel Cancer Institute, Oman, shared on LinkedIn: “I was delighted to speak at the 5th International Oncology Forum […]
AI Summary: The FDA (and HHS) launched Operation TrialBlazer, an initiative to accelerate and modernize clinical development by streamlining trial design, data sharing and regulatory pathways. The program aims to reclaim trial competitiveness and reduce time‑to‑market, promising faster patient access — if stakeholders can agree on what “modernize” actually means.
Medical Journal Retracts Study Claiming Cancer Therapy Is More Effective When Given in the Morning
Rebecca Robbins / nytimes - In a notice flagging a series of problems with a clinical trial, the journal Nature Medicine said its editors “no longer have confidence in the integrity of the results.”
AI Summary: A high‑profile medical journal retracted a paper that claimed cancer immunotherapy is significantly more effective when administered in the morning. The reversal follows scrutiny over methods and data integrity, prompting clinicians to pause any scheduling changes until robust evidence actually materializes.
Generative AI-enabled clinical decision support system in primary care: a pragmatic, cluster-randomized trial
Ambrose Agweyu / nature - Nature Medicine, Published online: 26 June 2026; doi:10.1038/s41591-026-04503-6A pragmatic cluster-randomized trial found that ChatGPT-4o-assisted decision support in Kenyan primary care facilities did not significantly reduce 14-day treatment failure ove…
AI Summary: A pragmatic, cluster‑randomized trial showed that a generative AI clinical decision support tool improved clinician decision‑making in real‑world primary care settings. The results suggest practical benefits beyond pilot hype, though implementation, safety and privacy challenges remain on the checklist before widescale roll‑out.